Merck has entered into an exclusive global licensing agreement with SciBrunch Therapeutics for SPR2015, a preclinical oral KRAS G12D inhibitor, in a transaction valued at up to $2.13 billion, including a $400 million upfront payment.
Final PAPILLON trial results show Johnson & Johnson’s RYBREVANT (amivantamab-vmjw) plus chemotherapy achieved a 34.3-month median overall survival in EGFR exon 20 insertion-positive NSCLC — the longest reported to date in this historically hard-to-treat population.
AstraZeneca has secured exclusive worldwide rights to Zegfrovy (sunvozertinib), Dizal Pharmaceutical’s oral EGFR inhibitor for EGFR exon 20 insertion non-small cell lung cancer, in a deal worth up to $1.5 billion. The agreement strengthens AstraZeneca’s EGFR-mutated lung cancer portfolio ahead of potential first-line expansion.
A new combination therapy has been shown to be the first and only chemotherapy-free treatment to demonstrate a significant survival advantage over the current standard of care for a specific type of lung cancer prevalent in Asia.
Eli Lilly announced its novel cancer drug, olomorasib, has been granted Breakthrough Therapy designation by the U.S. FDA. This significant milestone aims to expedite the development of the treatment for patients with advanced KRAS G12C-mutated non-small cell lung cancer, a historically difficult-to-treat condition.
